We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Common Antihistamine Nasal Spray Identified as Potential Anti-COVID-19 Drug

By HospiMedica International staff writers
Posted on 10 Jul 2020
Print article
Illustration
Illustration
Azelastine, an antihistamine currently available as a nasal spray, has been identified as a potential topical preventive or post-exposure anti-COVID-19 approach.

Azelastine was among several drugs in CEBINA GmbH’s (Vienna, Austria) COVID-19 drug repurposing project for the identification of commonly used approved drugs with activity against SARS-CoV-2 infection in in vitro assays. CEBINA has applied a computational approach, integrating several software tools and novel biological pathway analysis, to identify potential anti-COVID-19 drugs. This approach was complemented with in vitro viral infection testing with SARS-CoV-2 which showed that five generic drugs demonstrated anti-SARS-CoV-2 activity. The most potent among the identified drugs, Azelastine is available as a topically applied product and has only modest side-effects.

"As the number of COVID-19 cases continues to surge, the identification of Azelastine presents a highly promising preventive and/or post-exposure anti-COVID-19 solution, particularly considering that this drug is widely available as nasal spray and can act directly at the initial site of viral infection," said Eszter Nagy, MD PhD, CEO and founder of CEBINA. "We are working towards confirming our findings in a clinical study, especially the observation that a significantly lower dose might be effective. A lower dosage would be expected to reduce the known side effects, which are not significant though potentially unpleasant and could differentiate between the COVID-19 and the anti-allergic indications."

"We are thrilled to see that our in-silico approach has led to the identification of existing and readily available drugs that have proven anti-SARS-CoV-2 activity, as these findings can have an immediate beneficial effect in the fight against COVID-19," said Professor Robert Konrat, in a structural biologist from the University of Vienna.

Related Links:
CEBINA GmbH

Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Vital Signs Monitor
Vista 120 SC
New
3-Channel ECG
ECG-1003p

Print article

Channels

Critical Care

view channel
Image: Tissue plasminogen activator working to dissolving brain clot and improving blood flow to the part of the brain being deprived (Photo courtesy of American Heart Association)

Injecting Clot-Dissolving Drug After Removing Large Brain Artery Clot Improves Stroke Outcomes

Approximately 1 in 5 ischemic strokes, which are caused by a clot, occur due to a blockage in a large artery in the brain (large vessel occlusions). The standard treatment for this type of stroke is the... Read more

Surgical Techniques

view channel
Image: The KeyScope low-cost laparoscope enables high resolution surgical imaging (Photo courtesy of Barnes et al., doi 10.1117/1.BIOS.2.2.022302)

Low-Cost, Robust Laparoscope Addresses Cost, Power and Sterilization Challenges

Laparoscopic surgery, a minimally invasive technique, has revolutionized surgical practices in high-income countries. This method involves using a laparoscope to perform operations through small incisions,... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.